Does Ozempic Affect Testosterone? What GLP-1 Does to Hormone Levels

For most men with obesity-related low testosterone, semaglutide (Ozempic, Wegovy) raises testosterone rather than suppressing it — by attacking the metabolic root cause of functional hypogonadism. The picture is more nuanced for lean, healthy men, where the hormone effect is essentially flat.

How GLP-1 Drugs Interact With the Hormone Axis

Excess body fat drives testosterone down through two well-documented mechanisms: aromatase in adipose tissue converts testosterone to estradiol, and insulin resistance disrupts hypothalamic signaling that drives LH and FSH production. Fix the metabolic problem, and the hormonal dysfunction often resolves with it.

A meta-analysis of seven studies (n = 680 men) found GLP-1 receptor agonists raised total testosterone by roughly 1.39 ng/mL on average, while also increasing free testosterone, LH, FSH, and SHBG — all consistent with a restored hypothalamic-pituitary-gonadal axis, not a drug acting directly on testosterone production.[1][9] Critically, the testosterone gains correlated with the degree of weight loss, which points to weight-mediated mechanism as the primary driver rather than any direct androgenic effect.

In metabolically healthy, eugonadal men without obesity or diabetes, GLP-1 receptor agonists show no meaningful change in androgen levels.[4] The Endocrine Society Clinical Practice Guidelines on male hypogonadism distinguish functional (obesity-driven) hypogonadism from organic hypogonadism for exactly this reason — context matters enormously when interpreting hormone data.

If you're evaluating GLP-1 options through a men's health lens, Marek Health offers panel-based hormone monitoring alongside GLP-1 prescribing, which makes longitudinal tracking practical.

Semaglutide vs. TRT: Different Tools for Different Problems

A direct randomized comparison of liraglutide versus testosterone replacement in obese men with functional hypogonadism is instructive.[11] Both raised total testosterone and improved sexual symptoms, but liraglutide produced 7.9 kg of weight loss versus just 0.9 kg with testosterone gel — and liraglutide increased LH and FSH, preserving the body's own production signal, while exogenous testosterone suppressed gonadotropins through negative feedback.

A separate trial pitting semaglutide against TRT found that semaglutide significantly improved sperm morphology (from a median of 2% to 4% normal forms, p = 0.012) while the TRT group experienced measurable declines in sperm concentration and total count.[12] For men who want to preserve fertility, that tradeoff is clinically decisive. Fertility-sparing alternatives to TRT — including Clomid (clomiphene) and enclomiphene (Androxal) — work on the same gonadotropin-preserving logic, but GLP-1 agents go further by treating the underlying metabolic driver.

The Bhasin et al. 2018 Testosterone Trials (NEJM) established that testosterone replacement improves sexual function and bone density but doesn't resolve underlying metabolic disease — reinforcing that TRT and GLP-1 therapy aren't interchangeable, even when both move testosterone numbers in the right direction. For a deeper look at how semaglutide's systemic effects extend beyond weight, see our coverage of semaglutide and cognitive function.

Explore your advanced therapy options if you're weighing GLP-1 agents against hormone optimization protocols.

What the Sexual Side-Effect Signals Actually Mean

The predominantly favorable picture has a real asterisk. Pharmacovigilance data from the FDA Adverse Event Reporting System identified 182 GLP-1-related sexual adverse events between 2003 and 2024, including erectile dysfunction and reduced libido — mostly in men aged 40–60.[19] A retrospective insurance-claims analysis found higher rates of newly diagnosed ED among younger, non-diabetic men on semaglutide versus matched controls (1.47% vs 0.32%), though the authors flagged residual confounding and surveillance bias as significant limitations.[19]

Against that, a Mendelian randomization study found genetically proxied GLP-1 receptor activation was associated with a substantially lower ED risk (OR 0.493, 95% CI 0.430–0.565).[7] A cardiovascular outcomes trial with dulaglutide showed a modest but significant reduction in moderate-to-severe ED versus placebo (HR 0.92, p = 0.021). The JCEM literature is consistent: in metabolically impaired men, GLP-1 agents improve erectile function alongside cardiometabolic markers. The adverse signals likely reflect a small subpopulation — possibly lean men with no baseline metabolic driver — rather than a general hazard.

Baseline testosterone and sexual function screening before starting therapy is reasonable practice, particularly for men who already report symptoms. Related: our analysis of GLP-1 microdosing protocols in 2026 covers how dose selection affects the side-effect profile more broadly.

---

Frequently asked questions

Does Ozempic lower testosterone in men?

In most men with obesity or insulin resistance, Ozempic raises rather than lowers testosterone by driving weight loss and restoring hypothalamic-pituitary-gonadal signaling. A meta-analysis of seven studies found an average total testosterone increase of approximately 1.39 ng/mL following GLP-1 receptor agonist treatment.[9] In lean, metabolically healthy men without functional hypogonadism, testosterone levels are largely unchanged.

Can semaglutide replace TRT for low testosterone?

Semaglutide is not a testosterone replacement — it treats the metabolic conditions that suppress testosterone in obese men, allowing the body to restore its own production. Per Endocrine Society Clinical Practice Guidelines, functional hypogonadism caused by obesity should be addressed by treating the underlying condition first. For men with organic hypogonadism (primary or secondary test